Redx, Jounce announce recommended business combination
Combined group will have a strong clinical pipeline and proven expertise in the discovery and development of highly selective…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
fibrotic diseases
Bridge Biotherapeutics, Boehringer Ingelheim cancel agreement to develop BBT-877 for idiopathic…
Under the License Agreement, Bridge Biotherapeutics will regain all rights to BBT-877